-
Enesi Pharma’s ImplaVax® platform shortlisted for Best New Vaccine Technology/Platform at the Vaccine Industry Excellence (ViE) Awards 2020
2nd March 2020
OXFORD, UK – 02 Mar 2020 – Enesi Pharma announces that its proprietary ImplaVax® solid dose, needle-free device and formulation technology has been shortlisted as a finalist for the Best New Vaccine Technology/Platform Award, the winner of which will be revealed at the 13th Annual Vaccine Industry Excellence (ViE) Awards ceremony and gala dinner on… read more
-
Enesi Pharma’s ImplaVax® platform nominated for Best New Vaccine Technology/Platform at the Vaccine Industry Excellence (ViE) Awards 2020
4th February 2020
OXFORD, UK – 4 February 2020 – Enesi Pharma announces that its proprietary ImplaVax® solid dose, needle-free device and formulation technology has been nominated in the Best New Vaccine Technology/Platform category, at the 13th Annual Vaccine Industry Excellence (ViE) Awards. The ViE Awards honour and recognize the efforts, accomplishments, and positive contributions of companies and… read more
-
Enesi Pharma Presenting at the BIO CEO & Investor Conference, New York
31st January 2020
OXFORD, UK – 31 January 2020 – Enesi Pharma (“Enesi”), the innovative pharmaceutical company developing unique needle-free, unit solid dose vaccines, is attending and presenting at the upcoming BIO CEO & Investor Conference in New York, USA taking place from 10th – 11th February 2020. David Hipkiss, CEO, will be presenting Enesi’s innovative ImplaVax® platform… read more
-
Enesi Pharma Awarded Grant Funding to Develop and Evaluate ImplaVax® enabled Solid Dose Vaccines Targeting Measles and Rubella
Grant funding provided by the Bill & Melinda Gates Foundation
29th October 2019
OXFORD, UK – 29 October 2019 – Enesi Pharma (“Enesi”), the innovative pharmaceutical company developing unique injectable solid dose drug-device vaccine products, is delighted to announce that it has been awarded grant funding from the Bill & Melinda Gates Foundation. The funding will support a new project to evaluate Enesi’s ImplaVax® technology platform for enabling… read more
-
Enesi Pharma to participate at the World Vaccine Congress Europe from 29th – 31st October 2019
22nd October 2019
OXFORD, UK – 22nd October 2019 – Enesi Pharma (“Enesi”), the innovative pharmaceutical company developing unique injectable solid dose drug-device vaccine products, announces it is participating at the upcoming World Vaccine Congress Europe 2019 in Barcelona, Spain (29th – 31st October 2019). Enesi is a Silver Sponsor of the event and will also showcase its… read more
-
Enesi Pharma Secures Innovate UK Funding to Enable Scalable Aseptic Manufacturing of ImplaVax® enabled Solid Dose Viral Vector Vaccines
24th September 2019
OXFORD, UK – 24 September 2019 – Enesi Pharma (“Enesi”), the innovative pharmaceutical company developing unique injectable solid dose drug-device vaccine products, is delighted to announce that it has secured substantial funding from Innovate UK, the UK’s innovation agency, under the Biomedical Catalyst 2019 Round 1: Early and Late Stage Awards Initiative. The award of… read more
-
Enesi Pharma adds Global Vaccine and Infectious Disease Expert Steven Chatfield to its Scientific Advisory Board
1st July 2019
Oxford, UK – 1 July 2019. Enesi Pharma, the innovative pharmaceutical company developing unique injectable solid dose vaccine products, announces the appointment of Dr Steven Chatfield to its Scientific Advisory Board (SAB). Dr Chatfield is an internationally recognised vaccine and infectious disease expert and brings nearly 40 years’ experience in R&D, executive, board and advisory… read more
-
Enesi Pharma and BARDA Drive enter Public-Private Partnership to Develop ImplaVax® Solid Dose Vaccine Delivery Technology against Influenza
15th April 2019
OXFORD, UK – 15 April 2019 – Enesi Pharma (“Enesi”), an innovative pharmaceutical company developing unique injectable solid dose drug-device vaccine products, announces it has entered a public-private partnership with the U.S. Biomedical Advanced Research and Development Authority’s (BARDA) DRIVe (Division of Research, Innovation, and Ventures) initiative to develop new vaccines against influenza enabled by… read more
-
Enesi Pharma’s ImplaVax® platform shortlisted for Best New Vaccine Technology/Platform at the Vaccine Industry Excellence (ViE) Awards 2019
10th April 2019
OXFORD, UK – 10 April 2019 – Enesi Pharma announces that its proprietary ImplaVax® solid dose, needle-free device and formulation technology has been shortlisted for the Best New Vaccine Technology/Platform Award, the winner of which will be revealed at the 12th Annual Vaccine Industry Excellence (ViE) Awards 2019 ceremony and gala dinner on 15 April…. read more
-
Enesi Pharma to participate at World Vaccine Congress 2019 in Washington DC
10th April 2019
OXFORD, UK – 10 April 2019 – Enesi Pharma, an innovative pharmaceutical company developing unique injectable solid dose drug-device vaccine products, will participate at the World Vaccine Congress, taking place on 14-17 April in Washington, DC. The Company will showcase its ImplaVax® solid dose, needle-free device and formulation technology for the development of novel vaccine… read more
-
Enesi Pharma and University of Oxford collaborate to target plague with a novel ImplaVax®-enabled adenovirus-based solid dose vaccine
9th April 2019
OXFORD, UK – 09 April 2019 – Enesi Pharma (“Enesi”), an innovative pharmaceutical company developing unique injectable solid dose drug-device vaccine products and scientists at the world-renowned Oxford Vaccine Group (“OVG”) at the University of Oxford, announce they have entered into a collaborative agreement to create and test a solid dose vaccine against plague. The… read more
-
Enesi Pharma and GeoVax to Collaborate on Development of Multiple Vaccines Administered by ImplaVax® a Novel Needle-Free Vaccine Delivery Platform
2nd January 2019
Potential for Addressing Multiple Infectious Disease Targets OXFORD, UK and ATLANTA, GA – 2 January 2019 – Enesi Pharma, an innovative pharmaceutical company developing unique injectable solid dose drug-device vaccine products, and GeoVax Labs, Inc. (OTCQB: GOVX), a biotechnology company developing human vaccines, announced today a collaboration to develop solid-dose needle-free vaccine formulations utilizing GeoVax’s… read more
-
Enesi Pharma and Sementis sign R&D Collaboration focused on Needle-free Solid Dose Vaccines for Peanut Allergy and chikungunya/Zika Infection
5th November 2018
Oxford, UK and Melbourne, Australia – 5 November 2018. Enesi Pharma, an innovative pharmaceutical company developing unique injectable solid dose drug-device vaccine products, and Sementis, a biotechnology company developing innovative vaccine candidates for the prevention of allergies and infectious diseases, announce they have entered into a collaborative agreement. The collaboration is focused on the development… read more
-
Enesi Pharma Selected to Showcase Unique ImplaVax® Needle-Free Solid Dose Vaccine Platform in Inaugural ‘Lightning Talk’ Session at BARDA Industry Day
16th October 2018
Oxford, UK – 16 October 2018. Enesi Pharma, an innovative pharmaceutical company developing unique injectable solid dose vaccine products, is honoured to have been selected to present a ‘Lightning Talk’ at The Biomedical Advanced Research and Development Authority (BARDA) Industry Day on 29-30 October at the Grand Hyatt in Washington DC, U.S. BARDA is a key… read more
-
Enesi Pharma to showcase unique ImplaVax® Needle-Free Solid Dose Vaccine Platform at World Vaccine Congress Europe 2018
4th October 2018
Oxford, UK – 4 October 2018. Enesi Pharma, an innovative pharmaceutical company developing unique injectable solid dose drug-device vaccine products, announces it will showcase its innovative ImplaVax® needle-free solid dose vaccine platform at the upcoming World Vaccine Congress Europe 2018 in Lisbon, Portugal (29-31 October 2018). Enesi Pharma is once again a Silver Sponsor of… read more
-
Enesi Pharma and Public Health England Enter R&D Collaboration for Novel Needle-Free Solid-Dose Vaccine for Emergent Threat Pathogens
1st October 2018
Oxford, UK – 1st October 2018. Enesi Pharma, an innovative pharmaceutical company developing unique injectable solid dose vaccine products, announces it has entered a research and development collaboration with Public Health England (PHE), an executive agency of the UK Government’s Department of Health and Social Care. The collaboration is focused on the development and evaluation… read more
-
Enesi Pharma and Walter Reed Army Institute of Research (WRAIR) sign Cooperative R&D Agreement (CRADA) for Needle-Free Solid-Dose Vaccine for Shigella Infection
24th September 2018
Oxford, UK – 24th September 2018. Enesi Pharma, an innovative pharmaceutical company developing unique injectable solid dose vaccine products, announces it has entered a Cooperative Research and Development Agreement (CRADA) with the Walter Reed Army Institute of Research (WRAIR), a United States Department of Defense Laboratory, regarding Shigella vaccine development. The CRADA is focused on… read more
-
Enesi Pharma Drives Forward Growth Plans with Move to New State-Of-The-Art Headquarters in Oxford
20th September 2018
Oxford, UK – 20th September 2018. Enesi Pharma, an innovative pharmaceutical company developing unique injectable solid dose drug-device vaccine products, is delighted to announce the opening of its new headquarters including state-of-the-art research and development facilities in Milton Park, Oxford, in the heart of the UK’s dynamic life science cluster. Since its launch in 2017… read more
-
Enesi Pharma Welcomes Global Vaccine Expert James Cheyne to its Scientific Advisory Board
3rd September 2018
Oxford, UK – 3 September 2018. Enesi Pharma, an innovative pharmaceutical company developing unique injectable solid dose vaccine products, announces the appointment of James Cheyne to its Scientific Advisory Board (SAB). Enesi’s SAB comprises experts in vaccines and preventative health from leading academic, research and international health organisations across the US and Europe. Mr Cheyne… read more
-
Enesi Pharma presenting at the World Vaccine Congress, Washington – Wednesday 4 April 2018
29th March 2018
Enesi Pharma are attending the World Vaccine Congress, Washington 3-5 April 2018. David Hipkiss, CEO, will be presenting our latest developments in the Viral Vectors & Novel Platforms Technology Showcase entitled ImplaVaxTM , Unique needle free solid dose vaccine platform delivering enhanced immunogenicity with ultimate convenience and no cold chain at 10.25am on Wednesday, in Ballroom level… read more
-
Enesi Pharma appoints new international Scientific Advisory Board
6th November 2017
Oxford, UK – 6 November 2017. Enesi Pharma, a clinical-stage company developing unique injectable solid dose drug-device combination products, announces the formation of a new International Scientific Advisory Board (SAB). The SAB includes experts in vaccines and preventative health from leading academic/ research and international health organisations in the US and Europe. Commenting on the… read more
-
Enesi Pharma debuts at World Vaccine Congress
5th October 2017
Oxford, UK – 10 October 2017. Enesi Pharma, a clinical-stage company developing unique injectable solid dose drug-device combination products, announces its launch as a new company at the World Vaccine Congress, which takes place on 10-12 October in Barcelona, Spain. Enesi is focused on the development of innovative vaccines and therapeutics using its proprietary ImplaVax™… read more